Skip to content
Home/Companies/Biotech/KALA BIO
KALA BIO

KALA BIO

Biotech·US·Exited 2017·Held 3yr
Entry
2014
Hold
3yr
Exit
2017

Who owns KALA BIO?

KALA BIO was owned by Ysios Capital Partners through Ysios BioFund I (2008 vintage) from 2014 to 2017, exited via IPO.

Hand-verified · updated 2026-08-03

Ysios Capital Partners
Investor
Ysios Capital Partners
Ysios BioFund I · 2008 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusAcquired
Websitewww.kalarx.com
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2017

More from Ysios BioFund I

Other portfolio companies in the same fund.

Galecto Biotech
Exited 2020
BiotechDK· 2018
Sanifit
Exited 2021
BiotechES· 2015
to
AM Pharma
AM Pharma
Active
BiotechNL· 2011
MedLumics
Active
MedTechES· 2011
STAT-Diagnostica
Exited 2018
MedTechES· 2011
to
BioVex
Exited 2011
BiotechUS· 2009
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Kala BIO

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Kala BIO.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue